Saade YM, Nicol G, Lenze EJ, et al. - Researchers examined how comorbid anxiety symptoms influence antidepressant treatment remission in older adults with major depressive disorder (MDD). In this multisite clinical trial, they provided open-label protocolized treatment with venlafaxine extended release titrated to a maximum of 300 mg daily to 468 older adults aged 60 years or older with MDD. They used the Anxiety Sensitivity Index, the Brief Symptom Inventory anxiety subscale, and the Penn State Worry Questionnaire to assess anxiety at baseline. Outcomes revealed that comorbid anxiety symptoms were correlated with symptom severity but had no effect on antidepressant remission or time to remission.